Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia
Eight patients had a complete response within 1 month of infusion.
Hematologic Cancers
Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment
The model appears to predict minimal residual disease status.
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Additional Tablet Strengths of Xpovio Now Available
The additional strengths are intended to increase patient compliance and reduce pill burden.
First CAR T-Cell Therapy Approved for Indolent Follicular Lymphoma
The approval was based on data from the single-arm, open-label phase 2 ZUMA-5 study.
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Ukoniq Approved for Marginal Zone Lymphoma, Follicular Lymphoma
The approval was based on data from the open-label, multi-cohort phase 2 UNITY-NHL Trial.
Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
Xpovio Multiple Myeloma Indication Expanded
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
